Treatment News : Inflammatory Cells Linked to Earlier Death From AIDS, Hep C

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 28, 2014

Inflammatory Cells Linked to Earlier Death From AIDS, Hep C

Certain inflammatory markers are linked to an earlier death among alcohol abusers with HIV, including those coinfected with hepatitis C virus (HCV). This possibly helps explain why, despite antiretroviral (ARV) treatment, some HIV-positive people die before others. Publishing their findings in the journal AIDS, researchers followed 400 HIV-positive abusers of alcohol, half of whom also had hepatitis C, for three to five years between 2001 and 2009. The participants were tested for seven pro-inflammatory cytokines upon their entry into the study and were tracked through national databases to verify whether or not they had died by the study’s end.

Cytokines are proteins that alert white blood cells to flock to a zone of inflammation. In the short term, this process is good for the body; it is, for example, how the a bacterial or fungal infection is cleared. But in the long-term it is harmful. HIV causes chronic inflammation, and much current research in the field focuses both on how the inflammation harms the body and on ways to fight the inflammation.

Eighty-five of the participants eventually died, mostly of AIDS- or hepatitis C-related causes. The researchers found that higher indicators of inflammation were strongly linked to increased risk of death in these heavy drinkers. The connection remained regardless of whether or not an individual was taking ARVs. The inflammatory marker known as interleukin-6 (IL-6) had the most significant correlation to mortality.

“Current antiretroviral drug regimens may be able to improve mortality in most patients, but are unable to decrease the potentially dangerous burden of a chronic inflammatory state in the body,” Daniel Fuster, MD, PhD, a researcher at the Clinical Addiction Research and Education (CARE) unit at Boston University School of Medicine, and the study’s lead author, said in a release. “Additional research should explore how to better manage chronic inflammation in these patients.”

To read the study release, click here.

Search: Inflammatory markers, early death, alcohol abuses, HIV, hepatitis C virus, HCV, AIDS, cytokines, interleukin-6, IL-6, Daniel Fuster, Clinical Addiction Research and Education, CARE, Boston University School of Medicine.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.